Longevity & Aging · Metabolic & Cardiometabolic
testosterone therapy decreases fat mass
In plain terms: Does testosterone therapy help you lose fat?
Part of: 💊 Testosterone therapy (TRT)
Somewhat — it tends to trim fat (especially belly/visceral fat) and add muscle, shifting your body composition. But it's not a weight-loss drug: several trials, especially in obese or dieting men, found no real difference in fat or scale weight versus placebo.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Testosterone therapy tends to shift body composition — modestly lowering fat mass (especially visceral/abdominal fat) while raising lean mass — but the fat-loss effect is smaller and less consistent than the muscle effect. Several trials, particularly in obese men or men also dieting, found no significant difference in total fat or body weight versus placebo.
The evidence (19)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Azzi M et al 2026 · study_type: observational | observational | contradicts | moderate | 57 transmasculine adults followed 10 years on testosterone-based GAHT; weight, BMI, and waist circumference increased, and body composition showed higher trunk (android) fat distribution, not a fat-mass reduction. |
| Gopal RA et al. 2010 · Andrologia | RCT | tested-null | low | Crossover RCT (T2DM): no significant effect on insulin resistance, visceral fat, or anthropometrics. |
| Shigehara K et al 2026 · study_type: RCT | RCT | supports | moderate | 214 hypogonadal men in 4 arms (TRT+exercise, TRT-alone, exercise-alone, control); body fat percentage significantly decreased only in the TRT+exercise group at 6 months, over 1 year of testosterone enanthate 250mg IM. |
| Junjie W et al] # corrected 2026-08-17 from PubMed; was [Zhang J et al. 2019 · Aging Male | meta-analysis | tested-null | low | Meta 7 RCTs: no statistical effect on BMI, fat mass, or body composition overall. |
| Seminara G et al 2026 · study_type: RCT | RCT | supports | moderate | 10 obese hypogonadal 'late responder' men on tirzepatide; adding testosterone undecanoate 1000mg IM for 6 months produced significantly greater fat-mass reduction than tirzepatide alone (group B vs A, P<0.05). |
| Wang C et al. 2004 · J Clin Endocrinol Metab | RCT | supports | moderate | Long-term trial (n=163): lean mass up, fat mass down (both p=0.0001) maintained up to 42 months. |
| Guo C et al. 2016 · Andrologia | meta-analysis | tested-null | moderate | Meta 16 RCTs: fat mass reduced non-significantly (MD -0.85, p=0.06); no change in BMI/weight. |
| Ng Tang Fui M et al. 2016 · BMC Med | RCT | tested-null | moderate | RCT (obese, dieting): no difference in weight loss between TRT and placebo; symptomatic benefit only. |
| Griffith A et al 2025 · study_type: observational | n-of-1 | mixed | low | Single 52-year-old male on TRT plus lifestyle/probiotic intervention over 6 months; fat mass decreased 13.2 lb (~6 kg) with a 6.1% reduction in body-fat percentage. |
| Christensen LL et al. 2023 · J Clin Endocrinol Metab | RCT | supports | moderate | RCT (aging men): TRT reduced whole-body fat and subcutaneous adipose tissue vs placebo (24 weeks). |
| Korkmaz ES et al 2026 · study_type: observational | observational | supports | low | 15 transgender men on intramuscular testosterone for 12 months; body fat percentage decreased significantly while fat-free mass and weight increased (small retrospective cohort, no kg figure given). |
| Aversa A et al. 2010 · J Sex Med | RCT | supports | moderate | RCT (metabolic syndrome): TRT reduced waist circumference and visceral fat over 24 months; improved HOMA-IR. |
| Krause Neto W et al. 2015 · Aging Male | meta-analysis | supports | moderate | Meta 11 RCTs: fat mass decreased (estimate -1.78), high heterogeneity. |
| Barnouin Y et al. 2021 · J Clin Endocrinol Metab | RCT | mixed | moderate | RCT (obese frail >=65y): TRT attenuated but did not reverse diet-induced lean/BMD loss; no overall function benefit. |
| Mangolim AS et al. 2022 · Andrology | meta-analysis | mixed | moderate | Meta 16 RCTs (obese): lean gain + slight LDL improvement; waist/BMI effects heterogeneous, age-modified. |
| Kolla B et al 2025 · study_type: observational | observational | supports | low | 22 transmales followed 12 months on GAHT (testosterone); total subcutaneous fat decreased 5.9% while muscle mass increased 7.2%, alongside an opposite pattern (fat increase) in the 32 transfemales on estrogen therapy. |
| Isidori AM et al. 2005 · Clin Endocrinol (Oxf) | meta-analysis | supports | high | Meta 29 RCTs: total body fat -1.6 kg (-6.2% of baseline fat) vs placebo. |
| Gruenewald DA, Matsumoto AM 2003 · J Am Geriatr Soc | observational | supports | low | Systematic review: TRT increases lean mass and reduces fat mass in healthy older men with low-normal T. |
| Kapoor D et al. 2006 · Eur J Endocrinol | RCT | supports | moderate | Crossover RCT (T2DM hypogonadal): TRT reduced waist circumference (-1.63 cm) and waist/hip ratio. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.